Subscribe To
Cogent biosciences announces positive lead-in data from ongoing phase 3 peak trial evaluating bezuclastinib in combination with sunitinib in patients with gastrointestinal stromal tumors (gist)
– Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% ...
June 3, 2023, 6:15 pm
Cogent biosciences: bezuclastinib's potential in treating gastrointestinal stromal tumors
Cogent Biosciences is a biotechnology company focused on developing solutions for complex medical conditions, with a particular focus on Gastrointesti...
February 28, 2023, 2:17 am
Cogent biosciences: multiple inflection points for fy23, hold for now
Cogent Biosciences, Inc. is building momentum around its bezuclastinib compound. FY22 saw a number of p...
December 27, 2022, 7:02 pm
Cogent biosciences announces positive updated clinical data from ongoing phase 2 apex trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (advsm)
– 89% ORR in TKI-therapy naïve patients; 73% ORR in all evaluable patients with 27-week median follow-up – Rapid and deep responses seen includin...
December 11, 2022, 10:30 pm
Cogent biosciences to host investor webcast to discuss updated clinical data at ash from the ongoing phase 2 apex trial of bezuclastinib in patients with advanced systemic mastocytosis
WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on dev...
December 5, 2022, 8:00 am